Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma

Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

9 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 4
Recruiting: 2
Ph III recruiting: 0
Growth YoY: —
Industry share: 25%
Top sponsor: City of Hope Medical Center
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (4)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06692452	Tazemetostat Plus CHOP in 1L T-cell Lymphoma	withdrawn	Phase 2	0	Eric Jacobsen, MDOTHER	0	Apr 1, 2026	clinicaltrials
NCT04021082	CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)	withdrawn	Phase 2 / Phase 3	0	Portola PharmaceuticalsINDUSTRY	0	Feb 21, 2023	clinicaltrials